Clinical Research Article

Next Generation Sequencing Should Be Proposed to Every Woman With “Idiopathic” Primary Ovarian Insufficiency

Sarah Eskenazi,1,2,* Anne Bachelot,2,3,* Justine Hugon-Rodin,4,5,6 Genevieve Plu-Bureau,4,5,6 Anne Gompel,4,5 Sophie Catteau-Jonard,7 Denise Molina-Gomes,8 Didier Dewailly,7 Catherine Dodé,9 Sophie Christin-Maitre,1,2,10,† and Philippe Touraine2,3,†

1Department of Reproductive Endocrinology, Saint-Antoine Hospital, AP-HP, Paris, France; Center for Rare Growth Disorders and Center for Developmental Disorders: CMERC; 2Sorbonne University Medicine, Paris, France; 3Department of Endocrinology and Reproductive Medicine, Pitié-Salpêtrière Hospital, AP-HP, Paris, France; Center for Rare Endocrine Disorders and Center for Rare Gynecological Disorders: CMERC; 4Department of Gynecology and Endocrinology, Cochin/Port-Royal Hospital, AP-HP, Paris, France; 5Paris Descartes University, Paris, France; 6INSERM UMR 1153, EPOPE group, Paris, France; 7Department of Medical Gynaecology, CHU Lille, University of Lille, F-59000 Lille, France; 8Department of Assisted Reproductive Technics, Poissy Saint-Germain-en-Laye Hospital, Poissy, France; 9Department of Genetics and Molecular Biology, Cochin/Port-Royal Hospital, AP-HP, Paris, France; and 10INSERM UMR-S933, 75012 Paris, France

ORCiD numbers: 0000-0003-3036-5206 (S. Eskenazi); 0000-0001-8521-5163 (D. Dewailly); 0000-0002-8462-7753 (P. Touraine).

*Joint first authors.
†Joint last authors.

Abbreviations: FSH, follicle-stimulating hormone; NGS, next generation sequencing; PA, primary amenorrhea; POI, primary ovarian insufficiency; SIFT, Sorting Intolerant From Tolerant; SMD, secondary menstrual disturbance; VUS, variant of unknown significance.

Received: 19 August 2020; Editorial Decision: 23 February 2021; First Published Online: 1 March 2021; Corrected and Typeset: 1 June 2021.

Abstract

Context: Primary ovarian insufficiency (POI) affects 1% of women under 40 years of age. POI is idiopathic in more than 70% of cases. Though many candidate genes have been identified in recent years, the prevalence and pathogenicity of abnormalities are still difficult to establish.

Objective: Our primary objective was to evaluate the prevalence of gene variations in a large prospective multicentric POI cohort. Our secondary objective was to evaluate the correlation between phenotype and genotype.

Methods: Two hundred and sixty-nine well-phenotyped POI patients were screened for variants of 18 known POI genes (BMP15, DMC1, EIF2S2, FIGLA, FOXL2, FSHR, GDF9,
Primary (premature) ovarian insufficiency (POI) is defined as a loss of ovarian activity before the age of 40, and it is characterized by menstrual disturbances (amenorrhea or oligomenorrhea) with elevated gonadotropins (follicle-stimulating hormone [FSH] ≥ 25 IU/L) and low serum estradiol levels [1]. The incidence of POI is around 1 per 100 women [2, 3] overall, and 1 per 1000 women under the age of 30 years [4]. POI leads to infertility and an increased risk of osteoporosis and cardiovascular disease [5, 6]. Different mechanisms are known to be involved in the pathogenesis of POI: decreased primordial follicular pool at birth, accelerated follicular atresia, or a dysfunction of follicular growth [7]. Several causes of POI have been identified, including autoimmune or iatrogenic causes like chemotherapy or ovarian surgery [8]. Some authors have also suggested environmental causes [9, 10]. Genetic disorders involved include not only Turner syndrome (4-5% of cases of POI) and FMR1 (Fragile X Mental Retardation type 1) gene premutation (3% to 15% of cases of POI) [11], but also monogenic disorders (syndromic or nonsyndromic) [12, 13]. Around 70% of cases remain unexplained [11], though some of these cases of idiopathic POI may be linked to genetic abnormalities. In recent years, new genetic screening techniques have identified genetic alterations that may be linked to POI. Many familial studies have identified mutations involved in POI [14-17], and a few cohort studies have described variants of candidate genes or copy number variants [18-23]. Interestingly, a few studies have reported the use of next generation sequencing (NGS) to analyze a panel of candidate genes in patients with POI [24-26]. The prevalence of known genetic alterations is estimated at 20% to 25% [7]. The primary goal of our study was to describe the prevalence of genetic abnormalities of 18 candidate genes by NGS in a large cohort of 269 POI patients. The secondary goal was to evaluate the correlation between those abnormalities and the patients’ phenotype.

Materials and Methods

Patients

From January 2015 to January 2017, all patients newly diagnosed with POI in 5 different Reproductive Medicine Centers in France (La Pitié-Salpêtrière Hospital, Saint-Antoine Hospital, Port-Royal Hospital in Paris, Poissy/Saint-Germain-en-Laye Hospital, and Jeanne de Flandre Hospital, Lille) were included in this study. POI was diagnosed based on amenorrhea or oligomenorrhea associated with FSH levels above 25 IU/L and low serum estradiol levels, before the age of 40. Every patient underwent karyotyping of at least 20 cells and a FMR1 molecular analysis. We excluded patients found to have Turner syndrome based on the karyotype or any other karyotype abnormality, as well as patients with a FMR1 premutation. Patients who previously underwent gonadotoxic treatment (chemotherapy or pelvic radiation) or extensive ovarian surgery were also excluded from the study. All patients signed an informed consent form. The study was approved by the local ethics committee.

Clinical Data

Ethnic origin, family history of POI (at least 1 first-degree female relative with POI according to the patient), pubertal development, menstrual history (primary amenorrhea or secondary menstrual disturbance), and prior spontaneous pregnancies were recorded during the medical
consultations at diagnosis. Clinical symptoms suggesting syndromic POI were evaluated and any personal history of autoimmune disorders was noted. Furthermore, tests were done for 21-hydroxylase antibodies, ovarian antibodies, thyroid peroxidase antibodies, thyroglobulin antibodies, glutamate decarboxylase antibodies, antibodies common in celiac disease and lupus antibodies.

DNA Sequencing
Genomic DNA was extracted either from the patient’s blood cells or from a derived lymphoblastoid. The 18 genes studied were selected because of their potential implication in POI according to previous studies (Table 1). We tested for mutations in the coding exons and abutting splice sites of BMP15 (NM_005448.2), DMC1 (NM-007068.3), EIF2S2 (NM_003908.2), FIGLA (NM_001004311.3), FOXL2 (NM-023067.3), FSHR (NM_000145.3), GDF9 (NM_005260.5), GPR3 (NM_005281.3), HFM1 (NM_001017975.4), LHX8 (NM_00100933.1), MSH5 (NM-172165.3), NOBOX (NM_001080413.3), NRSK1 (NM_004959.4), PGRMC1 (NM_006667.4), STAG3 (NM_001282717.1), BHLHB9 (NM_001142528), FSHB (NM_001018080), and XPNPEP2 (NM_003399.5) using the Ion Torrent semiconductor sequencing technique. The primers were designed using the Ampliseq Designer software. The libraries were prepared from 50 ng of genomic DNA using the Ion Plus fragment library kit. Adapter ligation, nick repair, and amplification were performed according to the Ion Torrent protocol (Life Technologies). The Ion One Touch template kit was used for the emulsion polymerase chain reaction and enrichment steps. Sequencing of the amplicon libraries was done on the Ion Torrent PGM system with 316 chips, and the Ion Xpress barcode adapters kit was used for the barcoding. Version 2 of the Ion sequencing kit was used for all sequencing reactions, according to the recommended protocol. After sequencing, reads were mapped to the human genome 19 assembly with the Torrent mapping alignment program. Single-nucleotide variants and small insertions/deletions (indels) were identified using Torrent Variant Caller (Life Technologies) and Nextgene software [27]. All the mutations detected were confirmed by Sanger sequencing of new polymerase chain reaction products.

Nomenclature and In Silico Analyses of the Mutations
The effects of the missense variants were considered based on the results of functional tests described previously (when available). In the absence of a functional study, the effects of the missense variants were predicted using 3 different algorithms: Sorting Intolerant From Tolerant (SIFT) (sift.jcvi.org/www/SIFT_enst_submit.html), PolyPhen-2 (genetics.bwh.harvard.edu/pph2/), and MutationTaster (http://www.mutationtaster.org/). The SIFT and PolyPhen-2 algorithms gave scores ranging from 0 to 1. A mutation is predicted as “deleterious” by SIFT if its score is below 0.05; otherwise it is predicted as “tolerated”. A mutation is predicted as “possibly damaging” by PolyPhen-2 if its score is greater than 0.15, and as “probably damaging” if it is greater than 0.85; otherwise it is predicted as “benign”. The Mutation Taster algorithm indicates the probability of an alteration being a polymorphism or a disease-causing alteration. The scores range from 0 to 1, with a score of 1 indicating a high security of prediction.

We considered an alteration as pathogenic or a polymorphism based on the results of functional tests described previously. When no such tests had been done previously, we considered a missense variant as pathogenic when 2 of the 3 algorithms (SIFT, PolyPhen-2 and MutationTaster) gave identical results.

Missense variants can also affect the splicing of the primary transcripts. These effects of each missense variant were predicted using the MaxEntScan scoresplice (genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html), NNsplice (omictools.com/mssplice-tool), and Human Splicing Finder (rd-connect.eu/tools-resources/human-splicing-finder) algorithms.

Statistical Analysis
The statistical analyses were done using SAS software (SAS Institute, Inc., Cary, NC). The Student test and χ² test were used to assess the differences in the characteristics of the women between 2 groups according to genotype. The data are presented as a percentage (for qualitative variables) or mean and SD for quantitative variables. P < .05 was considered as statistically significant.

Results
Description of the Population
We included 269 consecutive patients diagnosed with POI. As shown in Table 2, 126 patients (52%) were of Caucasian origin, 57 (23%) came from sub-Saharan Africa, 50 (20%) were from North Africa, and 13 (5%) came from Asia (missing data N = 23). Forty-three patients (16%) had a family history of POI (missing data N = 5). Primary amenorrhea (PA) was observed in 34 patients (13%) and 229 patients (87%) (missing data N = 6) had a secondary menstrual disturbance (SMD) (amenorrhea or oligomenorrhea).
Table 1. A panel of 18 candidate genes

| Genes          | Location | Function(s)                                                                 | Reference of human POI description and functional study |
|----------------|----------|------------------------------------------------------------------------------|--------------------------------------------------------|
| BHLHB9 (NM_001142528) | Xq22.1   | Follicular activation, development and maturation, cell division              | [28]                                                   |
| BMP15 (NM_005448.2)    | Xp11.2   |                                                                              |                                                        |
| DMC1 (NM-007068.3)     | 22q13.1  | Meiosis                                                                      | [44]                                                   |
| EIF2S2 (NM_003908.2)   | EIF2B2-14q24.3; EIF2B4-2p23.3; EIF2B5-3q27.1 | Cell death, damage, autophagy                                                  | [29]                                                   |
| FIGLA (NM_001004311.3) | 2p13.3   | Oogenesis                                                                    | [45]                                                   |
| FOXL2 (NM-023067.3)    | 3q23     | Gonadogenesis–oogenesis                                                       | [46]                                                   |
| FSHR (NM_000145.3)     | 2p21-p16 | Follicular activation, development and maturation, hormonal support           | [47]                                                   |
| GDF9 (NM_005260.5)     | 5q31.1   | Follicular activation, development and maturation, cell division              | [48]                                                   |
| GPR3 (NM_003281.3)     | 1p36.1-p35 | Meiosis                                                                      | [30, 34]                                               |
| HFM1 (NM_001017975.4)  | 1p22.2   | DNA division and repair                                                       | [49]                                                   |
| LHX8 (NM_00100933.1)   | 1p31.1   | Oogenesis                                                                    | [50]                                                   |
| MSH5 (NM-172165.3)     | 2p13.1   | Meiosis                                                                      |                                                        |
| NOBOX (NM_001080413.3) | 7q35     | Gonadogenesis–oogenesis, follicular activation, development and maturation   | [51]                                                   |
| NR5A1 (NM_004959.4)    | 9q33     |                                                                               |                                                        |
| PGRMC1 (NM_006667.4)   | Xq24     | Hormonal support                                                              |                                                        |
| STAG3 (NM_001282771.1) | 11p14.1  | Cell division                                                                 |                                                        |
| FSHB (NC_000011.10)    | 7q22.1   | Follicular activation, development and maturation, hormonal support           | [52]                                                   |
| XPNPEP2 (NM_003399.5)  | Xq25     |                                                                              |                                                        |

Among the patients with PA, the prevalence of those with or without spontaneous pubertal development was 25% (N = 8) and 19% (N = 6) respectively. Eighteen patients (56%) had incomplete pubertal development (missing data N = 2). An SMD occurred before the age of 20 years in 30 patients (15%), between the age of 20 and 29 years in 47 patients (23%) and between the age of 30 and 39 years in 127 patients (62%). Ninety-six patients (37%) had been pregnant before the diagnosis of POI (missing data N = 25). Fifty-seven patients (23.5%) showed signs of autoimmunity (59% with thyroid antibodies).

Table 2. Clinical data of the cohort (N = 269 women)

|                                | N (%)     |
|--------------------------------|-----------|
| Ethnic origin                  |           |
| Caucasian                      | 126/246   | (52)                                |
| North Africa                   | 50/246    | (20)                                |
| Sub-Saharan Africa             | 57/246    | (23)                                |
| Asia                           | 13/246    | (5)                                 |
| Familial history of POI        | 43/264    | (16)                                |
| Primary amenorrhea             | 34/263    | (13)                                |
| No pubertal development        | 6/32      | (19)                                |
| Incomplete pubertal development| 18/32     | (56)                                |
| Complete pubertal development  | 8/32      | (25)                                |
| Age at secondary menstrual disturbance (years) |           |
| <20                            | 30/204    | (15)                                |
| 20-29                          | 47/204    | (23)                                |
| 30-39                          | 127/204   | (62)                                |
| Pregnancy before POI           | 96/259    | (37)                                |

Abbreviation: POI, primary ovarian insufficiency.

NGS Results

The NGS results are presented in Table 3. One hundred and two patients (38%) presented at least 1 abnormality, of 1 to 5 genes each. Forty-eight patients (18%) presented a VUS. Sixty-seven (25%) had at least 1 variant. Thirteen patients (5%) had at least 1 variant and 1 VUS.

Among the 18 genes tested, variants were identified for only 13 genes (Table 3) and 1 to 6 different variants were found for each. NOBOX variants were the most common autosomal gene variant (N = 24; 9% of the patients). Twenty patients shared DMC1 variants (7%). Nine patients presented BMP15 (3%) variants, 6 for HFM1 (2%),
## Table 3. Variants found in the cohort

| Gene     | DNA mutation | Protein alteration | rs number       | Polyphen-2 (score) | Sift (score) | Mutation taster (p-value) | Functional test                                           | No. of patients | PA/SMD |
|----------|--------------|--------------------|-----------------|-------------------|--------------|--------------------------|----------------------------------------------------------|----------------|--------|
| NOBOX    | c.131G>T     | p.Arg44Leu         | rs115206969      | B (0)             | NS           | P (1)                    | No effect [24, 55]. Protein instability [56]             | 3              | 0/3    |
|          | c.349C>T     | p.Arg117Trp        | rs7800847        | B (0.35)          | D (0.02)     | DC (0)                   | <transcriptional activity [24, 35, 55]                   | 7              | 1/6    |
|          | c.454G>A     | p.Gly152Arg        | rs201886397      | B (0)             | T (0.79)     | P (1)                    | <transcriptional activity [56]                          | 3              | 0/3    |
|          | c.1354G>A    | p.Asp452Asn        | rs112190116      | B (0)             | T (1)        | P (1)                    | No effect [24, 55] ? transcriptional activity [56]       | 4              | 1/3    |
|          | c.271G>T     | p.Gly91Trp         | rs77587352       | D (0.98)          | NS           | DC (0)                   | <transcriptional activity [24, 35, 55]                   | 5              | 2/3    |
|          | c.1064G>C    | p.Arg355Pro        | rs201947677      | D (0.99)          | D (0)        | DC (1)                   | p.Arg355Htc disrupts DNA binding [51]                    | 1              | 0/1    |
| BMP15    | c.443T>C     | p.Leu148Pro        | rs114823607      | D (0.983)         | D (0.97)     | P (0.89)                 | Disrupted mature protein secretion [57]                 | 8              | 0/7    |
|          |              |                    |                 |                   |              |                          |                                                          | 1              | 0/1    |
| HFM1     | c.11C>A      | p.Ser4             | rs376463557      | NS                | NS           | NS                       | Truncated and/or unstable protein                        | 1              | 1/0    |
|          | c.1477A>C    | p.Lys493Gln        | rs113908392      | D (0.95)          | D (0)        | DC (0.99)                |                                                          | 3              | 3/2    |
|          | c.2308G>A    | p.Asp770Asn        | rs143399622      | D (0.93)          | T (0.08)     | DC (1)                   |                                                          | 1              | 0/1    |
| NR5A1    | c.43G>A      | p.Val15Met         | rs104894124      | D (0.99)          | D (0)        | DC (1)                   | <DNA binding and transcriptional activity [58]          | 1              | 0/1    |
|          | c.386G>T     | p.Pro129Leu        | rs200749741      | B (0.12)          | D (0)        | DC (0)                   | <transcriptional activity [52]                          | 1              | 1/0    |
|          | c.772C>T     | p.Gln258           | NOVEL           | NS                | NS           | NS                       |                                                          | 1              | 0/1    |
|          | c.1093C>T    | p.Arg365Trp        | NOVEL           | D (0.94)          | D (0)        | DC (1)                   |                                                          | 2              | 0/2    |
| STAG3    | c.659T>G     | p.Leu220Arg        | NOVEL           | D (0.99)          | D (0)        | DC (1)                   |                                                          | 1              | 1/0    |
|          | c.939A>T     | p.Tryl313Phe       | NOVEL           | D (0.93)          | T (0.15)     | DC (1)                   |                                                          | 1              | 1/0    |
|          | c.1999G>T    | p.Arg667Cys        | rs141693812      | B (0.37)          | D (0.01)     | DC (1)                   |                                                          | 1              | 1/0    |
|          | c.2473C>G    | p.Leu825Val        | rs766488962      | D (0.84)          | T (0.4)      | DC (1)                   |                                                          | 1              | 1/0    |
|          | c.2612G>A    | p.Arg71His         | NOVEL           | D (0.98)          | T (0.07)     | DC (1)                   |                                                          | 1              | 1/0    |
| GDF9     | c.1275C>A    | p.Ser425Arg        | rs116926261      | D (0.53)          | T (0.5)      | ND                       | Pathogenic [59]                                         | 1              | 0/1    |
|          | c.1360C>T    | p.Arg454Cys        | rs61754582       | D (0.99)          | D (0.01)     | ND                       |                                                          | 3              | 0/5    |
| MSH5     | C.138-9msGAG | p.Glu46dup         | rs78109648       | NS                | NS           | NS                       | Potential splicing modification (HSF ~8.7%)             | 1              | 0/1    |
|          | c.416-1G>A   | p.?                | NOVEL           | —                 | —            | —                        |                                                          | 1              | 0/1    |
|          | c.952-2A>G   | p.?                | rs143453834      | —                 | —            | —                        |                                                          | 1              | 0/1    |
| FOXL2    | c.384G>T     | p.Trp128Cys        | NOVEL           | D (0.98)          | D (0)        | DC (1)                   |                                                          | 1              | 0/1    |
| XPNEP2   | c.754C>G     | p.Amg252Gly        | rs189381278      | D (0.99)          | D (1)        | DC (0.98)                |                                                          | 1              | 0/1    |
|          | c.1154A>G    | p.Lys385Arg        | rs145287846      | D (0.99)          | T (0.05)     | DC (0.98)                |                                                          | 1              | 0/1    |
| FIGLA    | c.274G>A     | p.Val92Met         | NOVEL           | D (0.99)          | D (0)        | DC (1)                   |                                                          | 1              | 0/1    |
| DMC1     | c.449G>A     | p.Gly150Asp        | rs58396845       | D (0.92)          | D (0)        | DC (1)                   |                                                          | 1              | 1/0    |
|          | c.598A>G     | p.Me200Val         | rs2227914        | B (0)             | D (0)        | P (1)                    | Unstable protein [38]                                   | 19             | 1/17   |
| FSHR     | c.334A>C     | p.Asn112His        | rs201909194      | D (0.90)          | T (0.42)     | P (0.85)                 |                                                          | 1              | 0/1    |
|          | c.1330G>A    | p.Ala444Thr        | rs202162496      | B (0.07)          | D (0)        | DC (1)                   |                                                          | 1              | 0/1    |
| LHX8     | c.974C>T     | p.Ala325Val        | rs34889850       | D (0.82)          | T (0.15)     | DC (1)                   |                                                          | 1              | 0/1    |

Abbreviations, B, benign; D, damaging; HSF, heat shock transcription factor; T, tolerated; NS, not scored; P, polymorphism; DC, disease causing; +/-, heterozygous; ~/, homozygous; PA, primary amenorrhea; SMD, secondary menstrual disturbance.

*Missing data N = 1.
of the patients with NOBOX variants originated from sub-Saharan Africa. Among the patients with a family history of POI, 21% presented with variants and most of them involved DMC1 (40%), followed by NOBOX and NR5A1 (20% each).

The phenotype/genotype analysis, as shown in Table 5, found no statistical difference between patients with or without variants regarding ethnic origin, familial history of POI, PA, age at the onset of an SMD, and previous history of natural pregnancy. As NOBOX variants were the variants most commonly observed, the patients with only NOBOX variants (homozygous N = 17, homozygous N = 1) were compared with those without the variant (Table 5). There was no statistically significant difference regarding phenotype between patients with NOBOX variants and patients without variant. Furthermore, phenotype was not different in patient presenting 1 variant compared

### Table 4. Patients with combined variants. N = 14

| Patients with combined variants | Genes | DNA mutation | Protein alteration | PA or SMD | Familial POI |
|--------------------------------|-------|--------------|-------------------|-----------|--------------|
| 1                              | BMP15 | c.443T>C     | p.Leu148Pro       | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 2                              | STAG3 | c.938A>T     | p.Tyr313Phe       | PA        | No           |
|                                | NOBOX | c.349C>T     | p.Arg667Cys       | No        | No           |
|                                | BMP15 | c.443T>C     | p.Leu148Pro       | SMD       | No           |
|                                | NOBOX | c.349C>T     | p.Arg117Trp       | No        | No           |
| 3                              | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
|                                | XPNP2 | c.754C>G     | p.Arg252Gly       | No        | No           |
| 4                              | NR5A1 | c.386C>T     | p.Pro129Leu       | PA        | No           |
|                                | HFM1  | c.11C>A      | p.Ser4*           | No        | No           |
| 5                              | NOBOX | c.349C>T     | p.Arg117Trp       | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 6                              | FSHR  | c.334A>C     | p.Asn112His       | SMD       | No           |
|                                | HFM1  | c.1477A>C    | p.Lys493Gln       | No        | No           |
| 7                              | HFM1  | c.1477A>C    | p.Lys493Gln       | SMD       | No           |
|                                | LHX8  | c.974C>T     | p.Ala325Val       | No        | No           |
| 8                              | NOBOX | c.131G>T     | p.Arg44Leu        | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
|                                | FIGLA | c.274G>A     | p.Val92Met        | No        | No           |
| 9                              | NOBOX | c.349C>T     | p.Arg117Trp       | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 10                             | NOBOX | c.131G>T     | p.Arg44Leu        | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 11                             | BMP15 | c.443T>C     | p.Leu148Pro       | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 12                             | NOBOX | c.131G>T     | p.Arg44Leu        | SMD       | No           |
|                                | DMC1  | c.598A>G     | p.Met200Val       | No        | No           |
| 13                             | BMP15 | c.443T>C     | p.Leu148Pro       | SMD       | No           |
|                                | BMP15 | c.443T>C     | p.Leu148Pro       | SMD       | No           |
| 14                             | NOBOX | c.271G>T     | p.Gly91Trp        | PA        | No           |
|                                | NOBOX | c.271G>T     | p.Gly91Trp        | No        | No           |

Abbreviations: SMD, secondary menstrual disturbance; PA, primary amenorrhea; POI, primary ovarian insufficiency.
patients with combined variants (data not shown). The sole patient with a variant of the FOXL2 gene presented with blepharophimosis, ptosis, and epicanthus inversus syndrome.

In our cohort, 38% of patients with at least 1 variant had a spontaneous pregnancy before the diagnosis of POI. Among the 24 patients with a NOBOX variant, 8 had been pregnant. All were heterozygous for the NOBOX variant, but 3 had additional variants of other genes such as DMC1 for patient 1, DMC1 and FIGLA for patient 2, and BMP15, XPNPEP2 and DMC1 for patient 3. Among the 9 patients with BMP15 variants, 5 had been pregnant. All were heterozygous for the BMP15 variant but 2 had additional variants of other genes such as DMC1 for 1 of them. The other patient has been described previously as having a NOBOX variant.

### Discussion

To our knowledge, this is the largest study to report NGS results and the correlation between genotype and phenotype in a POI cohort, after excluding other identified POI etiologies, such as iatrogenic POI, Turner syndrome and patients with FMR1 premutation.

Only a few studies have tested POI patients using NGS technology to date. Fonseca et al. reported an NGS analysis combined with Sanger sequencing that found 4 variants of 3 genes in a small cohort of 12 POI patients [26]. Bouilly et al. screened a cohort of 100 POI patients for 19 loci. Nineteen percent of the patients were identified with at least 1 variant [24]. In a cohort including 69 patients, Patiño et al. found 48% of patients with variants of 49 genes among the 420 candidate POI genes tested using NGS combined with Sanger sequencing [19]. None of these studies included a statistical genotype/phenotype analysis.

We used NGS to determine that 38% of our patients had at least 1 variant that may be involved in the onset of POI, though it is difficult to establish causality between genetic abnormalities found by NGS and POI. Interestingly, none of our POI patients presented variants of 5 genes that have previously been implicated in the pathophysiology of POI (EIF2S2, GPR3, PGRMC1, BHLHB9, FSHB) [28-34]. This suggests that these genetic variants are not a major cause of POI.

Upon analysis of our patients’ clinical data with respect to the presence of variants, we did not find any statistically significant difference in the phenotype according to the genotype.

With regard to the menstrual cycle, Bouilly et al. reported PA in 20% of mutated patients [24]. In our study, 17% of patients with variants presented with PA. On the other hand, among all POI patients with variants, SMD occurred mainly after the age of 30 (49%). This result is quite unexpected, as deleterious variants could be linked to earlier ovarian deficiency, though this does match the results of Patiño et al., who reported that 62% of cases of secondary amenorrhea occurred after the age of 30 in mutated patients [19].

There does seem to be a relationship with the ethnic origin, as a higher prevalence of POI has been described in the African American population than in Japanese women [3]. In our study, 52% of patients with a variant came from sub-Saharan Africa and 58% of those patients presented a NOBOX variant, though this prevalence may

| Table 5. Clinical characteristics of POI patients with or without variant found in NGS sequencing |
|---------------------------------------------|------------------|------------------|------------------|------------------|
| **Total**                                  | No variant N (%) | All variants N (%) | NOBOX Variants N (%) | P** |
| Ethnic origin                              |                  |                  |                  |      |
| Caucasian                                  | 99/183 (54)      | 27/63 (43)       | 9/17 (53)        |      |
| North Africa                               | 48/183 (26)      | 2/63 (3)         | NS               |      |
| Sub-Saharan Africa                         | 25/183 (14)      | 32/63 (51)       | 7/17 (41)        |      |
| Asian                                      | 11/183 (6)       | 2/63 (3)         | 0                |      |
| Familial POI                               | 33/197 (17)      | 10/67 (15)       | NS               |      |
| Primary amenorrhea                         | 23/201 (11)      | 11/65 (17)       | 5/18 (28)        | .11  |
| Age at secondary menstrual disturbance (years old) |                  |                  |                  |      |
| <20                                        | 24/155 (15)      | 6/49 (12)        | 1/13 (8)         |      |
| 20-29                                      | 29/155 (19)      | 18/49 (37)       | 5/13 (38)        | NS   |
| 30-39                                      | 102/155 (66)     | 23/49 (51)       | 7/13 (54)        |      |
| Spontaneous pregnancy before POI           | 71/194 (37)      | 25/65 (38)       | NS               |      |

**Abbreviations:** NGS, next generation sequencing; NS, not significant; POI, primary ovarian insufficiency.

**P all variants versus no variant.

Excluding patients with combined variant in other genes.

P NOBOX variant versus no variant.
be underestimated because most of our patients were of Caucasian origin. Our NOBOX variant findings are similar to those of the study of Bouilly et al., in which 58% of patients with NOBOX variants came from sub-Saharan Africa [35]. We did not find any NOBOX mutations among Asian patients, as reported previously in 2 cohorts including only Chinese patients [36, 37].

Sixteen percent of our cohort mentioned at least 1 case of POI in the family. According to previous studies, 4% to 31% of cases of POI are familial forms [8]. It is noteworthy that familial cases of POI among our patients did not present more variants than nonfamilial cases, even when there were several variants. However, these data should be viewed with caution as we determined the family history based on questionnaires. Hormonal testing of family members was not available.

In our cohort, 37% of patients had been pregnant before the diagnosis of POI. Previous studies have described pregnancy before diagnosis in around 20% of patients [18]. Interestingly, the occurrence of a pregnancy before diagnosis was similar among patients with or without variants.

Furthermore, patients with NOBOX and BMP15 mutations (genes known to be involved in folliculogenesis) had been spontaneously pregnant before the diagnosis of POI and some of those were found to have combined variants of different genes. Therefore, other mechanisms may account for the secondary amenorrhea after fertility.

Previous studies have suspected and even underscored the polygenic pathogenesis of POI [19, 24]. In our cohort, 5% of patients had more than 1 variant. This is in line with Patiño et al. who used whole exome sequencing to find 5% of patients with 2 mutations [19]. In their study, all genetic disorders were considered together, whereas, in our study, we were able to distinguish between variants and variants of unknown significance.

Bouilly et al. found that most patients presenting with PA had 2 genetic defects (3 of 5 patients). In the same study, the mean age at onset of POI was lower in patients with 2 combined variants than in patients with only 1 (17 versus 27) [24]. In contrast, in our study, the age at onset of PA and the age at onset of a secondary menstrual disturbance did not differ between patients with combined variants or with only 1 single variant. Therefore, no gene “dose effect” was not found in our study.

There are several possible hypotheses explaining the absence of phenotype/genotype correlations. The first is that all the genes we analyzed have different pathogenicities, which may have influenced our results. Indeed, it is challenging to determine the pathogenicity of each individual genetic abnormality. For example, the DMC1-p.Met200Val variant is common among the African population and has been considered as a polymorphism by other groups, though biochemical analyses have shown that the variant has reduced stability, and is only moderately effective at catalyzing in vitro chromosomal recombination reactions [38]. Moreover, it has been shown that different types of variants of a single gene may result in variable phenotypes [39]. A second hypothesis is the influence of nongenetic factors in the development of POI. Few studies have focused on the possible environmental causes of POI and most of those were animal studies. A recent review of 19 studies (animal and human data) described phthalates, bisphenol A, pesticides, and tobacco as the substances most often reported to have a negative impact on ovarian function, with increased follicular depletion leading to earlier menopause [9]. In their work, Béranger et al. underscored the impact of exposure to 2-bromopropane, perfluorooctanoate and cadmium on ovarian reserve [10]. The study of Gallichio et al. also supports a toxic origin, as it reported a higher prevalence of POI among Caucasian hairdressers using hair dyes without gloves [40]. Environmental causes could modulate the expression of certain genes involved in POI.

Our study is interesting for several reasons. To our knowledge this is the largest POI cohort tested with NGS. Our study focused on “idiopathic” POI as we excluded known causes of POI. Patients who presented autoantibodies were not excluded of the analysis. Indeed, positive autoantibodies were mostly represented by anti-thyroid autoantibodies, which are positive in 15% of euthyroid women [41]. Moreover, the autoimmune nature of POI is not always clear since a positive antibody does not mean that there are organic consequences and genetic disorders may be involved in these patients. We performed a thorough genetic analysis to classify the variants as deleterious variants or VUS. We are the first to report that there is no correlation between the patient’s phenotype and genetic results. Our study emphasizes that NGS should be proposed to every POI patient, regardless of their clinical presentation. Finding a mutation in a candidate gene may help to accept the diagnosis of POI, as depression is common in these patients [42]. Furthermore, accepting the diagnosis may improve the patient’s compliance with hormonal replacement therapy, as women with POI often stop their treatment [6]. Finally, identifying a mutation may be particularly relevant for female relatives, to whom fertility preservation could then be proposed.

Nevertheless, we should point out the multiple weaknesses of our study. Indeed, although more than 70 genes have been identified as candidate genes in the literature [43], we only tested 18. However, those genes were chosen as the genes most commonly identified previously in women with POI. Several human cases had
been reported in the literature for each gene. As for the clinical data, we should remember that determining the age of onset of POI can be challenging because, in some patients, amenorrhea occurs when stopping oral contraceptives to become pregnant. Furthermore, it would have been very useful to evaluate familial cases in greater detail. Studying the segregation of variants among our families with a history of POI could illustrate their involvement in the occurrence of POI. However, DNA samples could not be obtained from the patients’ relatives in most cases.

In conclusion, genetic screening would improve the care of patients diagnosed with “idiopathic” POI. Furthermore, performing NGS on POI patients would help geneticists to better understand the pathogenicity of the various genes implicated. One major remaining challenge will be to predict the age of onset of POI in women according to their genetic defect.

Additional Information

Correspondence: Philippe Touraine, Department of Endocrinology and Reproductive Medicine, Pitié-Salpêtrière Hospital, AP-HP, 47–83 Boulevard de l’Hôpital 75013, Paris, France. Email: Philippe.touraine@aphp.fr.

Disclosures: The authors report no conflict of interest in this work.

Data Availability: Some or all data generated or analyzed during this study are included in this published article or in the data repositories listed in References.

References

1. Webber I, Davies M, Anderson R, et al; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-937.

2. Haller-Kikkatalo K, Uibo R, Kurg A, Salumets A. The prevalence and phenotypic characteristics of spontaneous premature ovarian failure: a general population registry-based study. Hum Reprod. 2015;30(5):1229-1238.

3. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod. 2003;18(1):199-206.

4. Coulam CB, Adamson SC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol. 1986;67(4):604-606.

5. Christin-Maire S. The role of hormone replacement therapy in the management of premature ovarian failure. Nat Clin Pract Endocrinol Metab. 2008;4(2):60-61.

6. Bachelot A, Nicolas C, Gricourt S, et al. Poor compliance to hormone therapy and decreased bone mineral density in women with premature ovarian insufficiency. PLoS One. 2016;11(12):e0164638.

7. Persani L, Rossetti R, Cacciatore C. Genes involved in human premature ovarian failure. J Mol Endocrinol. 2010;45(5):257-279.

8. Beck-Peccoz P, Persiani L. Premature ovarian failure. Orphanet J Rare Dis. 2006;1:9.
of 14 families and review of the literature. *Hum Mutat.* 2016;37(12):1354-1362.

26. Fonseca DJ, Patoño LC, Suárez YC, et al. Next generation sequencing in women affected by nonsyndromic premature ovarian failure displays new potential causative genes and mutations. *Fertil Steril.* 2015;104(1):154-62.e2.

27. Louvrier C, Pasmant E, Briand-Suleau A, et al. Targeted next-generation sequencing for diagnostic differentiation of neurofibromatosis type 2, schwannomatosis, and meningiomatosis. *Neuro Oncol.* 2018;20(7):917-929.

28. De Vos M, Devroey P, Fauser BC. Primary ovarian insufficiency. *Lancet.* 2010;376(9744):911-921.

29. Fogli A, Gauthier-Barichard F, Schiffmann R, et al. Screening for known mutations in EIF2B genes in a large panel of patients with premature ovarian failure. *BMC Womens Health.* 2004;4(1):8.

30. Kovanci E, Simpson JL, Amato P, et al. Oocyte-specific G-protein-coupled receptor 3 (GPR3): no perturbations found in 82 women with premature ovarian failure (first report). *Fertil Steril.* 2008;90(4):1269-1271.

31. Layman LC, Shelley ME, Huey LO, Wall SW, Tho SP, McDonough PG. Follicle-stimulating hormone beta gene structure in premature ovarian failure. *Fertil Steril.* 1993;60(5):852-857.

32. Mansouri MR, Schuster J, Badhai J, et al. Alterations in the expression, structure and function of progesterone receptor membrane component-1 (PGRMC1) in premature ovarian failure. *Hum Mol Genet.* 2008;17(23):3776-3783.

33. Matthews CH, Borgato S, Beck-Pecco P, et al. Primary amenorrhea and infertility due to a mutation in the beta-subunit of follicle-stimulating hormone. *Nat Genet.* 1999;35(5):83-86.

34. Zhou S, Wang B, Ni F, Wang J, Cao Y, Ma X. GPR3 may not be a potential candidate gene for premature ovarian failure. *Reprod Biomed Online.* 2010;20(1):53-55.

35. Bouilly J, Bachelot A, Broutin I, Touraine P, Binart N. Novel NOBOX loss-of-function mutations account for 6.2% of cases in a large primary ovarian insufficiency cohort. *Hum Mutat.* 2011;32(10):1108-1113.

36. Qin Y, Shi Y, Zhao Y, Carson SA, Simpson JL, Chen Z-J. Mutation analysis of NOBOX homeodomain in Chinese women with premature ovarian failure. *Fertil Steril.* 2009;91(4 Suppl):1507-1509.

37. Zhao XX, Suzumori N, Yamaguchi M, Suzumori K. Mutational analysis of the homeobox region of the human NOBOX gene in Japanese women who exhibit premature ovarian failure. *Fertil Steril.* 2005;83(6):1843-1844.

38. Hikiba J, Hirota K, Kagawa W, et al. Structural and functional analyses of the DMCI-M200V polymorphism found in the human population. *Nucleic Acids Res.* 2008;36(12):4181-4190.

39. Wang Q, Li D, Cai B, et al. Whole-exome sequencing reveals SALL4 variants in premature ovarian insufficiency: an update on genotype-phenotype correlations. *Hum Genet.* 2019;138(1):83-92.

40. Gallicchio L, Miller S, Greene T, Zacur H, Flaws JA. Premature ovarian failure among hairdressers. *Hum Reprod.* 2009;24(10):2636-2641.

41. Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T4, and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab.* 2002;87(2):489-499.